Company / Operating Cash Flow
BIOCRYST PHARMACEUTICALS INC Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$347.4M
FY2025
5-year range
-$161.8M / $347.4M
FY2021-FY2025
Trend
+767.8%
vs FY2024
Sector context
#32 of 216
Health Care
What the data says
Operating Cash Flow changed +768% YoY in FY2025, a notable deviation from the 9-year average annual change of +76%.
Based on SEC 10-K filings.
$347M in FY2025. Top quartile in the Health Care sector.
Improved from -$95M to $347M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 216This company $347.4M Sector average $659.0M
▼
-47.3% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 767.8% year-over-year.
- Ranks #32 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $347.4M | +767.8% |
| FY2024 | -$52.0M | +45.3% |
| FY2023 | -$95.1M | +41.2% |
| FY2022 | -$161.8M | -13.9% |
| FY2021 | -$142.2M | -5.2% |
| FY2020 | -$135.1M | -50.8% |
| FY2019 | -$89.6M | +3.2% |
| FY2018 | -$92.6M | -125.0% |
| FY2017 | -$41.1M | +23.0% |
| FY2016 | -$53.4M | -307.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026